40107-07-1

Basic information

• Product Name: 4-CHLORO-6-IODOQUINOLINE
• Synonyms: 4-CHLORO-6-IODOQUINOLINE;BUTTPARK 89\01-03
• CAS NO: 40107-07-1
• Molecular Formula: C₉H₅ClIN
• Molecular Weight: 289.5
• Product Categories: CHIRAL CHEMICALS
• Mol File: 40107-07-1.mol

Chemical Properties

• Melting Point: 138-140℃
• Boiling Point: 338℃
• Flash Point: 158℃
• Appearance: /
• Density: 1.919
• Vapor Pressure: 0.000193mmHg at 25°C
• Refractive Index: 1.726
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.81±0.16(Predicted)
• CAS DataBase Reference: 4-CHLORO-6-IODOQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-IODOQUINOLINE(40107-07-1)
• EPA Substance Registry System: 4-CHLORO-6-IODOQUINOLINE(40107-07-1)

Safety Data

• Hazardous Substances Data: 40107-07-1(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
4-Chloro-6-iodoquinoline is utilized as a key intermediate in the synthesis of pharmaceuticals and biologically active compounds. Its unique structure allows for the creation of new molecules with potential therapeutic effects.
Used in Antimalarial Research:
In the field of antimalarial drug development, 4-chloro-6-iodoquinoline is studied for its potential as an antimalarial agent, offering a new avenue for combating malaria, a disease that affects millions worldwide.
Used in Antibacterial Applications:
4-Chloro-6-iodoquinoline is also investigated for its antibacterial activity, which could contribute to the development of new antibiotics to address the growing issue of antibiotic resistance.
Used in Organic Material Development:
4-CHLORO-6-IODOQUINOLINE is employed in the development of various organic materials, where its specific properties can enhance the performance of these materials in different applications.
Used as a Building Block in Chemical Synthesis:
4-Chloro-6-iodoquinoline serves as a building block for the synthesis of other chemicals, providing a foundation for creating a diverse range of chemical products with various applications across industries.

InChI:InChI=1/C9H5ClIN/c10-8-3-4-12-9-2-1-6(11)5-7(8)9/h1-5H

Upstream product

• 21873-51-8 6-iodoquinolin-4(1H)-one 
• 540-37-4 p-aminoiodobenzene 
• 909344-69-0 5-{[(4-iodophenyl)amino]methylidene}-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 342617-07-6 4-hydroxyl-6-iodoquinoline 

Downstream Products

• 749916-89-0 4-chloro-6-(4-tolyl)quinoline 
• 878276-92-7 4-chloro-6-(4-chlorophenyl)quinoline 
• 500127-41-3 4-chloro-6-(4-methoxyphenyl)quinoline 
• 766557-83-9 4-chloro-6-(phenylethynyl)quinoline 
• 1062590-01-5 3-[(6-iodo-4-quinolinyl)amino]-4-methylphenol 
• 49713-56-6 4-chloro-6-(trifluoromethyl)quinoline 
• 1219101-03-7 4-chloro-6-quinolinesulfonyl chloride 
• 1912423-48-3 4-chloro-6-(isopropylthio)quinoline 
• 219763-83-4 4-chloroquinoline-6-carbonitrile 

Relevant articles and documents

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

RIP2 kinase was recently identified as a therapeutic target for a variety of autoimmune diseases. We have reported previously a selective 4-aminoquinoline-based RIP2 inhibitor GSK583 and demonstrated its effectiveness in blocking downstream NOD2 signaling in cellular models, rodent in vivo models, and human ex vivo disease models. While this tool compound was valuable in validating the biological pathway, it suffered from activity at the hERG ion channel and a poor PK/PD profile thereby limiting progression of this analog. Herein, we detail our efforts to improve both this off-target liability as well as the PK/PD profile of this series of inhibitors through modulation of lipophilicity and strengthening hinge binding ability. These efforts have led to inhibitor 7, which possesses high binding affinity for the ATP pocket of RIP2 (IC50 = 1 nM) and inhibition of downstream cytokine production in human whole blood (IC50 = 10 nM) with reduced hERG activity (14 μM).

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of R

AMINO-QUINOLINES AS KINASE INHIBITORS

Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.

QUINOLYL AMINES AS KINASE INHIBITORS

Disclosed are compounds having the formula: wherein R1, R2, R3, R4 and R5 are as defined herein, and methods of making and using the same.

Compounds and Methods of Treatment

A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.

Thiazolinone 4-monosubstituted quinolines

Thiazolinone monosubstituted quinoline derivatives where the quinoline ring is mono-substituted at the 4 positions which derivatives demonstrates CDK1 antiproliferative activity and are useful as anti-cancer agents.

NOVEL QUINOLINE DERIVATIVES

The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).